NovaTears®
Dry Eye Disease
CommercialActive
Key Facts
About Novaliq
Novaliq is a private, clinical-stage biotech pioneering a novel, water-free drug delivery platform (EyeSol®) for ophthalmology. Its technology is designed to enhance drug bioavailability, retention time, and tolerability on the ocular surface. The company has achieved its first commercial approvals in the US for dry eye disease (NOV03, CyclASol) and is advancing a pipeline targeting glaucoma, diabetic retinopathy, dermatology, and uveitis. With a seasoned management team and strategic partnerships, Novaliq is positioned to challenge the standard of care in topical ocular therapeutics.
View full company profileTherapeutic Areas
Other Dry Eye Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Elate Ocular® | Cambium Bio | Phase 3 |
| OT-301 | Ocumension Therapeutics | Phase 2 |
| Avarept® Ophthalmic suspension 0.3% | Senju Pharmaceutical | Approved |
| Dry Eye Care Portfolio | YD Bio | Commercial |
| Dry Eye Studies | Oculus Research | Not Applicable (Service Provider) |
| MediPrint Lens (Dry Eye) | MediPrint Ophthalmics | Pre-clinical/Research |
| Tivanisiran | Sylentis | Phase 2/3 |
| A197 | Aramis Biosciences | Phase 2 |
| KM102 | Theratome Bio | Pre-clinical |
| iTEAR®100 Commercialization | Olympic Ophthalmics | Commercial |
| HydraD | EyeD Pharma | Pre-Clinical |
| ST-100 (Vezocolmitide) | Stuart Therapeutics | Phase 3 |